Robert Bristow MD PhD FRCPC
Clinician-Scientist and
Professor,
Radiation Oncology and Medical Biophysics,
Princess Margaret Hospital &University of Toronto
Head,CFCRI-PMH Prostate Cancer Rearch Program
Princess Margaret Hospital
University Health Network SAMO Workshop-April 2010-Lucerne
•Radiation therapy is often cited as an excellent option for locally advanced prostate cancer becau of available data including randomized studies
•Probable microscopic N1dia in locally advanced T3-T4and high-risk prostate cancers treated with WPRT+prostate RT+AD
•However no randomized data comparing surgery and radiation therapy available
-Data and comparisons between treatment options should
企业彩铃制作be analyzed with extreme caution in the abnce of
randomized trials data
-Comparing clinical and pathologic staging
-Radiotherapy improves outcome beyond long-term AD alone
in high-risk/locally advanced prostate cancer
北极熊会游泳吗
-Higher RT do can lead to decread metastas;not all cT3
have metastas and could be cured from local therapy alone
-Whole pelvic RT+prostate RT decreas local and systemic failure when ud with concurrent and
adjuvant AD
-Newer IMRT-IGRT technique allows for escalation of do and volumes to pelvic lymph nodes:extended PLND data may alter pelvic RT fields
-Bony and soft tissue metastas:oligometastas may be amenable to SBRT-localized ablative techniques(<5mets)to increa dia-free interval and possible cure
-Need better imaging and biomarkers of nodal involvement
One standard of care is pelvic+
prostatic radiotherapy+
concurrent/adjuvant hormonal
therapy for2-3years.
EORTC22863415pts
RTOG85-31,977pts
RTOG86-10,451pts
RTOG94-131310pts
SPCG-7/875pts
SFUO-3
设置输入法>科技感字体Bolla et al Lancet2002360:103-106骆驼英文
Median fu66month;
16%OS advantage78%vs62%社区矫正人员思想汇报
功能需求分析
好评语30字
Al-Mamgani,Prostate,2009
